mg. every 6 hours for 10 days, during which time the surgeon suspended surgical procedures. Recommendations were made regarding infection prevention practices; these were undertaken by the surgeon.

Although soft tissue infection following sclerotherapy may be underreported, large case series have not noted this complication in the past (2,3); this finding suggests that any soft tissue infection following sclerotherapy should be investigated. These cases highlight the need for vigilance when considering infection control for minor procedures that take place outside of the support of hospital-based infection control services.

Soft tissue infections as complications following varicos vein sclerotherapy appear to be rare (1–3). The Australian Aethoxysklerol study reported no cellulitis in 16,804 legs injected with the sclerosing agent, and superficial thrombophlebitis occurred at a rate of 0.08% at 2-year review (2). Likewise, a multicenter registry with 22 European phlebology clinics reported no cellulitis or necrotizing fasciitis in 12,173 sessions (3).

Similarly, surgical site infections with Group A *Streptococcus* spp. are uncommon. A multicenter survey of 72 centers worldwide reported all β-hemolytic *Streptococcus* spp. (including group A and group G) accounted for <5% of infections (4), while surveillance in the 1990s by Centers for Disease Control and Prevention reported <1% of all surgical wound infections was caused by group A *Streptococcus* spp. (5). A Canadian study reported invasive group A *Streptococcus* infections following surgery in 1.1 cases per 100,000 admissions (6). Outbreaks have been infrequently described (5,7–10), and sources of colonization range from throat to anus and vagina.

**Acknowledgments**

We thank Rosemary Lester and Michelle Cullen for their input.

**References**

1. Puisségur Lupo ML. Sclerotherapy: review of results and complications in 200 patients. J Dermatol Surg Oncol. 1989;15:214–9.
2. Conrad P, Malouf GM, Stacey MC. The Australian polidocanol (aethoxysklerol) study: results at 2 years. Dermatol Surg. 1995;21:334–6.
3. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg. 2005;31:123–8.
4. Koontz FP. Trends in post-operative infections due to group A streptococci. Int J Antimicrob Agents. 2000;16(Suppl 1):S35–7.
5. Mastro TD, Farley TA, Elliott JA, Facklam RR, Perks JR, Hadler JL, et al. An outbreak of surgical-wound infections due to group A *Streptococcus* carried on the scalp. N Engl J Med. 1990;323:968–72.
6. Daneman N, McGeer A, Low DE, Tyrrell JS, Koenig MG. Hospital outbreak of invasive group A streptococcal infections in Ontario, Canada, 1992–2000. Clin Infect Dis. 2005;41:334–42.
7. Kolmos HJ, Svendsen RN, Nielsen SV. The surgical team as a source of post-operative wound infections caused by *Streptococcus pyogenes*. J Hosp Infect. 1997;35:207–14.
8. Viglione A, Nottebart VF, Bodman HA, Platt R. Recurrent group A streptococcal carriage in a health care worker associated with widely separated nosocomial outbreaks. Am J Med. 1991;91:329S–33S.
9. Paul SM, Genese C, Spitalny K. Postoperative group A beta-hemolytic *Streptococcus* outbreak with the pathogen traced to a member of a healthcare worker’s household. Infect Control Hosp Epidemiol. 1990;11:643–6.
10. Schaffner W, Lefkowitz LB Jr, Goodman JS, Koenig MG. Hospital outbreak of infections with group A streptococci traced to an asymptomatic anal carrier. N Engl J Med. 1969;280:1224–5.

**Hiu-Tat Chan,* Jillian Low,† Lorraine Wilson,† Owen C Harris,* Allen C Cheng,† and Eugene Athan†**

*St. John of God Pathology, Geelong, Victoria, Australia, and †Barwon Health, Geelong, Victoria, Australia*

**Streptococcus suis in Humans, Thailand**

To the Editor: *Streptococcus suis* is an important zoonotic pathogen for swine and humans. Among 33 serotypes, serotype 2 is more frequently isolated from diseased pigs than other serotypes (1). However, not all serotype 2 strains are virulent, and degree of virulence varies among strains (2). Previous studies have reported several *S. suis* putative virulence factors, including the polysaccharide capsule, the muramidase-released protein, the extracellular factor, and suilysin (3–5). Some of these factors have been used as virulence-associated markers, and the association of the factors of *S. suis* isolates with virulence or clinical background has been suggested in Europe (2,5). However, because many virulent isolates lacking these factors have also been isolated from clinical cases in Canada (6), they cannot be used as virulence markers in North America.

Recent analysis of *S. suis* isolates by multilocus sequence typing (MLST) suggested the association of some clonal groups with particular clinical manifestations. That is, most invasive isolates belonged to the sequence type (ST) 1 complex, while the ST27 and ST87 complexes were found to include a higher proportion of lung isolates (7). Although *S. suis* has been prevalent worldwide, the geographic location of the isolates used so far was mainly Europe, North America, and East Asia (7–9). Moreover, the clonal association with virulence of *S. suis* has been discussed mainly on the basis of clinical and experimental data in swine (7). In this report, to broaden understanding of the population structure of *S. suis* as a zoonotic agent, we characterize 20 *S. suis* isolates (Table) recovered from humans in Thailand in 1998–2002.

Serotyping by coagglutination tests showed that 19 of the 20 isolates
belonged to serotype 2, while the remaining 1 (MNCM07) was serotype 14. MLST analysis resolved the 20 isolates into 8 STs (Table). By using eBURST (http://eburst.mlst.net), we assigned 4 isolates (MNCM01, MNCM06, MNCM07, and MNCM16) from 1 case of endocarditis and 3 cases of meningitis to the ST1 complex. The remaining isolates were assigned to the ST27 complex with a less-stringent group definition (Table), although ST101 (MNCM21) and ST104 (MNCM50) shared only 2 alleles with the ST27 complex with a less-stringent approach that defines an ST complex by sharing of alleles at >5 of the 7 loci.

All the isolates assigned to the ST1 complex were positive for the suilysin gene sly, the extracellular factor gene epf or its variant, and the muramidase-released protein gene mrp or its variant. With the exception of MNCM21 and MNCM50, which had only sly, all isolates classified into the ST27 complex were negative for sly and epf but positive for mrp or its variant. These results showed the congruence between STs and the virulence-associated gene profiles and further support the usefulness of MLST for epidemiologic studies of S. suis.

Of the 3 major clonal complexes identified so far in S. suis (ST1, ST27, and ST87), the ST1 complex particularly attracts considerable public attention as a clonal group that may have the potential for a higher degree of virulence than the others (7), and most (96%) of the human isolates investigated so far, including ST7 isolates, which caused the largest outbreak in China, belong to the ST1 complex (7–9). In this study, although no ST7 isolate was found, 4 isolates were assigned to the ST1 complex. This further confirmed the gravity of the ST1 complex not only for swine industries but also for public health.

In contrast to the ST1 complex, only 4 human clinical isolates have so far been reported to belong to the ST27 complex. Three of the 4 are isolates from Canada that belong to ST25

| Isolate no.† | Year of isolation | Site of isolation | Virulence-associated genes‡ | Serotype | Diseases and symptoms | ST (ST complex) |
|-------------|-----------------|-----------------|---------------------------|----------|----------------------|----------------|
| MNCM01      | 2000            | Blood           | cps2J/sly+epf+/mrp+       | 2        | Endocarditis         | 1 (1)          |
| MNCM06      | 2000            | Blood, CSF      | cps2J/sly+epf+/mrp+       | 2        | Neck stiffness, deafness (meningitis) | 1 (1)          |
| MNCM16      | 2000            | CSF             | cps2J/sly+epf+/mrp+       | 2        | Neck stiffness (meningitis) | 1 (1)          |
| MNCM07      | 2000            | Blood, CSF      | cps1J/sly+epf*/mrp+       | 14       | Neck stiffness (meningitis), death | 11 (1)         |
| MNCM04      | 2000            | Blood           | cps2J/sly–epf–mrp–        | 2        | Neck stiffness, deafness (meningitis) | 25 (27)# |
| MNCM10      | 2000            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia           | 25 (27)# |
| MNCM24      | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Endocarditis         | 25 (27)# |
| MNCM26      | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Endocarditis, deafness (meningitis) | 25 (27)# |
| MNCM51      | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia, diarrhea, death | 25 (27)# |
| MNCM55      | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia, diarrhea | 25 (27)# |
| LPH4        | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia, diarrhea | 25 (27)# |
| LPH12       | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia, diarrhea | 25 (27)# |
| MNCM43      | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Endocarditis         | 28 (27)        |
| MNCM21      | 1998            | CSF             | cps2J/sly–epf–mrp–        | 2        | Meningitis           | 101 (27)# |
| MNCM25      | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Neck stiffness (meningitis), diarrhea, death | 102 (27)# |
| MNCM54      | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Neck stiffness (meningitis), diarrhea | 102 (27)# |
| MNCM33      | 2002            | Blood, CSF      | cps2J/sly–epf–mrp–        | 2        | Neck stiffness (meningitis) | 103 (27)# |
| LPH3        | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Meningitis           | 103 (27)# |
| LPH5        | 2001            | Blood           | cps2J/sly–epf–mrp–        | 2        | Septicemia           | 103 (27)# |
| MNCM50      | 2002            | Blood           | cps2J/sly–epf–mrp–        | 2        | Pulmonary edema, death | 104 (27)# |

*ST, sequence type; CSF, cerebrospinal fluid.
†Isolates with MNCM number and LPH number were isolated from patients at Maharaj Nakorn Chiang Mai Hospital and Lamphun Hospital, Thailand, respectively.
‡Virulence-associated gene profiling was done as described previously (10). cps1J and cps2J, serotype 1 (and 14) and 2 (and 1/2) specific genes, respectively, involved in the capsular biosynthesis; sly, suilysin gene; epf, extracellular factor gene; mrp, muramidase-released protein gene; *, positive; –, negative.
§epf+, an epf variant that produces an ~3,000-bp fragment by PCR with primers described previously (10); mrp** and mrpS, mrp variants that produce ~1,800-bp and ~750-bp fragments, respectively, by PCR with primers described previously (10).
¶Coagglutination reaction using anti-serotype 2 serum was weak.
The remaining 1 is from Japan and assigned to ST28 (8). Unlike in previous reports, 80% of the human clinical isolates (16 isolates) characterized in this study were assigned to the ST27 complex. Although previous studies suggested that members of the ST27 complex may have lower potential to cause invasive diseases in swine (7), all the isolates were isolated from blood or cerebrospinal fluid of the patients, suggesting a high degree of invasiveness (Table). Because it is unknown whether the ST27 complex is also dominant among isolates from diseased pigs in Thailand, future surveillance will be necessary to know the situation in pigs. However, our data indicate that the ST27 complex is another clonal group that should be assessed for its importance for human infection. Because mmp, epf, and sly are not appropriate as virulence markers for the ST27 complex members, development of novel virulence markers will be needed for efficient discrimination of S. suis strains virulent for humans.

This study made use of the Streptococcus suis Multilocus Sequence Typing website (http://ssuis.mlst.net); this site is hosted at Imperial College and development is funded by the Wellcome Trust. The study was supported by a grant-in-aid from the Zoonoses Control Project of the Ministry of Agriculture, Forestry and Fisheries. The study was supported by a grant-in-aid from the Zoonoses Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan and the Endowment Fund for Medical Research, Faculty of Medicine, Chiang Mai University.

Daisuke Takamatsu,* Korawan Wongsawan,† Makoto Osaki,* Hiroto Nishino,‡ Tomono Ishiji,§ Prasit Tharavichitkul,† Banyong Khantawa,† Achara Fongcom,¶ Shinji Takai,# and Tsutomu Sekizaki*,**

*National Institute of Animal Health, Tsukuba, Ibaraki, Japan; †Chiang Mai University, Chiang Mai, Thailand; ‡Northern District Livestock Health and Hygiene Office, Mito, Ibaraki, Japan; §Seibu Livestock Hygiene Service Center, Tonami, Toyama, Japan; ¶Lamphun Provincial Hospital, Lamphun, Thailand; #Kitasato University, Towada, Aomori, Japan; and **Gifu University, Gifu, Gifu, Japan

References
1. Staats JJ, Feder I, Okwumabua O, Chengappa MM. Streptococcus suis: past and present. Vet Res Commun. 1997;21:381–407.
2. Vecht U, Wisselink HJ, van Dijk JE, Smith HE. Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depends on phenotype. Infect Immun. 1992;60:550–6.
3. Jacobs AAC, Loeffen PLW, van den Berg AJG, Storm PK. Identification, purification, and characterization of a thiol-activated hemolysin (suihlisin) of Streptococcus suis. Infect Immun. 1994;62:1742–8.
4. Smith HE, Danman M, van der Velde J, Wagenaar F, Wisselink HJ, Stockhofe-Zurwieden N, et al. Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infect Immun. 1999;67:1750–6.
5. Vecht U, Wisselink HJ, Jellema ML, Smith HE. Identification of two proteins associated with virulence of Streptococcus suis type 2. Infect Immun. 1991;59:3156–62.
6. Gottschalk M, Lebrun A, Wisselink H, Dubreuil JD, Smith H, Vecht U. Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2. Can J Vet Res. 1998;62:75–9.
7. King SJ, Leigh JA, Heath PJ, Luque I, Tarrradas C, Dowson CG, et al. Development of a multilocus sequence typing scheme for the pig pathogen Streptococcus suis: identification of virulent clones and potential capsular serotype exchange. J Clin Microbiol. 2002;40:3671–80.
8. Chang B, Wada A, Ikebe T, Olnishi M, Mita K, Endo M, et al. Characteristics of Streptococcus suis isolated from patients in Japan. Jpn J Infect Dis. 2006;59:397–9.
9. Ye C, Zhu X, Jing H, Du H, Segura M, Zheng H, et al. Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis. 2006;12:1203–8.
10. Silva LMG, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentijn-Weigand P. Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet Microbiol. 2006;115:117–27.